References
- ZhengRZengHZuoTLung cancer incidence and mortality in China, 2011Thorac Cancer201671949926816543
- ZhangYEpidemiology of esophageal cancerWorld J Gastroenterol201319345598560624039351
- LowDEEvolution in surgical management of esophageal cancerDig Dis2013311212923797119
- SongZBLinBCLiBPreoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinomaKaohsiung J Med Sci2013291266266624296054
- SongZZhangYSecond-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinomaOnco Targets Ther201471875188125342911
- HamamotoYKitagawaYCurrent perspective of treatment for advanced esophageal squamous cell carcinomaNihon Shokakibyo Gakkai Zasshi2014111225325924500314
- QuWFuJDYangFClinical implications of PTEN and VEGF expression status, as well as microvessel density in esophageal squamous cell carcinomaOncol Lett20151031409141526622682
- ShihCHOzawaSAndoNUedaMKitajimaMVascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagusClin Cancer Res2000631161116810741747
- YangPWHsiehMSHuangYCHsiehCYChiangTHLeeJMGenetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinomaPLoS One201496e10032624945674
- DingJChenXGaoZMetabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humansDrug Metab Dispos2013411195121023509226
- LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
- LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol2016341448145426884585
- ChenMQChenCLuHJXuBHThe efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinomaJ Thorac Dis20157101749175526623097
- LeeSJKimSKimMCapecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II studyBMC Cancer20151569326468007
- ShiYQinRWangZKDaiGHNanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinomaOnco Targets Ther2013658559123737672
- TianJShangMShiSBHanYXuJCetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinomaCancer Chemother Pharmacol201576482983426330330
- LiXLinWWangHLinWLinSLinYPhase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinomaMed Oncol201330474624122256
- AzizMASeryaRALasheenDSDiscovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agentsSci Rep201662446027080011
- GhavamipourFShahangianSSSajediRHArabSSMansouriKAghamaaliMRDevelopment of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding siteFEBS J2014281194479449425132001
- HuXZhangJXuBMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInt J Cancer201413581961196924604288
- SongZYuXLouGShiXZhangYSalvage treatment with apatinib for advanced non-small-cell lung cancerOnco Targets Ther2017101821182528367065